Navigation Links
Tuberculosis drug shows promise against latent bacteria
Date:9/12/2008

A new study has shown that an investigational drug (R207910, currently in clinical trials against multi-drug resistant tuberculosis strains) is quite effective at killing latent bacteria. This revelation suggests that R207910 may lead to improved and shortened treatments for this globally prevalent disease.

Despite numerous treatment advances, tuberculosis (TB) remains a serious disease fueled by co-infection of HIV patients, the rise of drug-resistant strains, and the ability of Mycobacterium tuberculosis to become dormant and linger in the lungs. In fact, one third of the world population is infected, asymptomatically, with latent TB and is at risk of developing active TB disease during their life time.

Anil Koul and colleagues at Johnson & Johnson tested R207910 on dormant M. tuberculosis in three different laboratory models of latency. R207910 targets a protein (ATP synthase) essential for making cellular energy (ATP) in actively replicating TB. The researchers reasoned that even dormant bacteria, which are essentially physiologically "turned off", still need to produce small quantities of ATP to survive. As such, a block in ATP synthesis might be an Achilles heel for killing dormant bacteria.

This reasoning proved to be correct and R207190 was able to kill dormant bacteria by greater than 95% whereas current drugs like isoniazid had no effect. Surprisingly, they found that R207910 is slightly more effective in killing dormant bacteria as compared to actively replicating ones, a unique spin as all known TB drugs are more effective on replicating bugs. Koul and colleagues hope to validate these results clinically, and note that ATP synthase should be looked at as a drug target for other persistent bacterial infections.


'/>"/>

Contact: Nick Zagorski
nzagorski@asbmb.org
301-634-7366
American Society for Biochemistry and Molecular Biology
Source:Eurekalert

Page: 1

Related biology news :

1. Preventing tuberculosis reactivation
2. Cornell researcher seeks clues to how tuberculosis infects cells
3. New drug targets may fight tuberculosis and other bacterial infections in novel way
4. Vitamin E may increase tuberculosis risk in male smokers with high vitamin C intake
5. Source of drug-tolerant tuberculosis possibly behind TB relapses, intensity of treatment
6. Excavated Jericho bones may help Israeli-Palestinian-German team combat tuberculosis
7. Potential new drug target to fight tuberculosis identified
8. Clinical trial for new tuberculosis vaccine
9. Research shows skeleton to be endocrine organ
10. Clones on task serve greater good, evolutionary study shows
11. Study shows link between alcohol consumption and hiv disease progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... VEGAS , Dec. 18, 2014   LaunchKey ... built for the post-password and Internet of Things era, ... seed funding. The venture round was led by Metamorphic ... Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has ... new funding to expand its team and bring LaunchKey ...
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 ... has licensed its PerformTek biometric technology to industry leaders ... their highly accurate, clinically validated, biometric wearable products. These ... January 6-9 in Las Vegas . ... the technology is accurate, flexible and robust – with ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the ... APAC Region 2015-2019"  report to their offering. ... market is advances in technology. With continuous advances ... solutions to the latest standard that meets the ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... you are overweight and pregnant, your baby isn,t destined to ... research report published online in The FASEB Journal ... show that modifying fat intake during pregnancy to a moderate ... mother,s size. Specifically, they found that a protein called "SIRT1" ...
... This release is available in Spanish . ... United States as a source of sugar for syrup and ... make it uniquely suited to production as a bioenergy crop, ... an ideal candidate because of its drought tolerance, adaptability to ...
... industry are excellent sources of proteins and healthy oils ... moment these side streams are mainly used as fish ... waste. Coordinated by VTT, the APROPOS (Added value ... project seeks to enrich several co-stream components at once ...
Cached Biology News:Eating well during pregnancy reduces baby's obesity risk regardless of mom's size 2Sorghum eyed as a southern bioenergy crop 2Food industry's high-quality co-streams used effectively as raw material for new products 2
(Date:12/24/2014)... Dec. 24, 2014   BioLife Solutions , Inc. ... and marketer of proprietary clinical grade hypothermic storage ... precision thermal shipping products for cells and tissues  ... hold its 2015 Annual Meeting of Stockholders on May ... expected date for the Annual Meeting represents a change ...
(Date:12/24/2014)... 2014 On Friday, December 19, ... the Omnibus and Continuing Resolution Appropriations Act of ... a condition eligible to receive funding through the ... the Department of Defense (DoD). The Hydrocephalus Association ... Capitol Hill, is celebrating this victory for the ...
(Date:12/24/2014)... December 23, 2014 Pipette.com announces their ... Twitter followers can submit their #HolidayInTheLab pictures for a ... lab mates. , For those struggling to think of ... Pipette.com Holiday in the Lab Contest provides the ideal ... followers to send pictures of their chemistree, holiday ...
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, ... it has filed a Clinical Trial Application (CTA) with ... products Regulatory Agency (MHRA) seeking regulatory approval to initiate ... molecule, Anatabine Citrate. Contingent on the Company ... a Phase I trial to assess the safety, tolerability ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... Wis. - Its not news that Wisconsin trails national ... whys of it are broken down and detailed in ... Venture Capital published by NorthStar Economics, Inc. The ... capital for Wisconsin companies. , ,The Wisconsin Technology Network ...
... Bays Nsight Telservices (www.nsighttel.com) in 2001 as Vice President ... as Chief Technical Officer (CTO) of Chicago startup BidBuyBuild. ... NET Cable, and NetNet and heads up the company's ... deployment. , , WTN: How did your dot-com ...
... more difficult challenges in business is turning around a sick ... the company is forced into bankruptcy. Realizing the painful reality ... impossible for owners and senior executives to deal with truthfully. ... them, and they will close that big outstanding proposal, and ...
Cached Biology Technology:Growing Venture Capital in Wisconsin 2Growing Venture Capital in Wisconsin 3Interview: WTN Gets Real with Appletons Brad Hansen - Dot-Com Experience helps Executive to Spot Trends 2Interview: WTN Gets Real with Appletons Brad Hansen - Dot-Com Experience helps Executive to Spot Trends 3Turning Around a Sick Company 2
100 g monoclonal antibody which can immunocapture ~10 g of Complex IV from heart mitochondria. Also included are 2 mg of bovine heart mitochondria for control immunocapture....
Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
Rabbit polyclonal to GPR56 ( Abpromise for all tested applications). entrezGeneID: 9289 SwissProtID: Q9Y653...
Annexin V Binding Buffer, 10X Concentrate Buffer , 50 ml Consult technical datasheet for details....
Biology Products: